Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma

Skin Cancer

Predictive value of [(18)F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: Real world data from the largest melanoma centres in the Netherlands

Eur J Cancer

Wilson MJ, Schurink AW, Schrage Y, Wouters MWJM, van Houdt WJ, Grunhagen DJ, van Thienen HV, van de Wiel BA, van der Hiel B, Kuijpers AMJ

doi: 10.1016/j.ejca.2026.116691

Breast Cancer

The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease

J Clin Oncol

Hunter NB, Parsons HA, Cope L, Canzoniero JV, Navarro FCP, El-Refai S, Anampa JD, Sparano JA, Rimawi M, Storniolo AM, Mainor C, Nanda R, DeMichele A, Gupta GP, Stringer-Reasor EJ, Lynce F, Cobain EF, Puhalla S, Jankowitz R, Rexer B, Mayer I, Hwang ES, Blackwell K, El Ayass W, Lee Y, Tweed C, Wilkinson M, Pennisi A, Sun B, Wright P, Gralow JR, Chen R, Boyle SM, Stearns V, Wolff AC, Park BH

doi: 10.1200/JCO-25-02934

Genitourinary Cancer

Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium

Lancet Oncol

Blackmur JP, van der Mijn JCK, Warren AY, Browning L, Burgers F, Hirsch MS, Kapur P, Mehra R, Rao P, Signoretti S, Bex A, Stewart GD, van Montfoort ML, Jones JO, International Neoadjuvant Kidney Cancer Consortium

doi: 10.1016/S1470-2045(25)00345-6

Skin Cancer

Neoadjuvant Intralesional Targeted Immunocytokines (Daromun) in Stage III Melanoma

Ann Oncol

Kähler KC, Hassel JC, Ziemer M, Rutkowski P, Meier F, Flatz L, Gaudy-Marqueste C, Zimmer L, Santinami M, Russano F, von Wasielewski I, Eigentler TK, Maio M, Zalaudek I, Haferkamp S, Quaglino P, Welzel J, Röcken C, Enk A, Simon JC, Świtaj T, Garzarolli M, Amaral T, Malissen N, Livingstone E, Elia G, Covelli A, Lorizzo K, Neri D, Mulatto S, Parca A, Pizzichi B, Ascierto PA, Garbe C, Robert C, Schadendorf D, Hauschild A

doi: 10.1016/j.annonc.2025.06.014

Gastrointestinal Cancer

Is pathological complete response a surrogate for overall survival in neoadjuvant clinical trials for gastroesophageal adenocarcinoma?

Eur J Cancer

Leite LF, Noronha MM, Menezes S, Conceição LDD, Costa de Almeida LF, Cappellaro AP, Belotto M, Peixoto RD', Baccili Cury Megid T

doi: 10.1016/j.ejca.2026.116602

Gastrointestinal Cancer

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial

JAMA Oncol

Zhang GQ, Meyerhardt JA, Shi Q, Twombly T, Pederson L, Ma C, Väyrynen JP, Zhao M, Takashima Y, Shergill A, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Tan B, O'Reilly EM, Giannakis M, Ogino S, Jurdi A, Sharma S, Aleshin A, Shields AF, Nowak JA

doi: 10.1001/jamaoncol.2025.5144

Gynecologic Cancer

Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis

Eur J Cancer

Secchi M, Signorelli M, Rulli E, Maruccio M, Di Martino G, Spadaro D, Giudice E, Turinetto M, Landoni F, Restaino S, Vizzielli G, Martinelli F, Lorusso D

doi: 10.1016/j.ejca.2025.116116

Genitourinary Cancer

Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis

BJU Int

Roessler N, Miszczyk M, Gontero P, Dematteis A, Miyajima K, Inoue S, Oberneder K, von Deimling M, Schuettfort VM, Vetterlein MW, Szabados B, Rajwa P, Karakiewicz PI, Teoh JY, Fisch M, Shariat SF

doi: 10.1111/bju.70214

Skin Cancer

Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients

J Clin Oncol

Lodde GC, Hassel JC, von Wasielewski I, Meier F, Mohr P, Kähler K, Hauschild A, Glutsch V, Stege H, Berking C, Hüning S, Huynh J, Gutzmer R, Reinhardt L, Schilling B, Loquai C, Erdmann M, Stang A, Kowall B, Galetzka W, Roesch A, Tilkorn D, Ugurel S, Zimmer L, Schadendorf D, Forschner A, Livingstone E

doi: 10.1200/JCO-24-02776

Related content

Predictive value of [(18)F]FDG PET/CT and index lymph node response following neoadjuvant pembrolizumab in resectable stage 3 melanoma: Real world data from the largest melanoma centres in the Netherlands

The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease

Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium

Neoadjuvant Intralesional Targeted Immunocytokines (Daromun) in Stage III Melanoma

Is pathological complete response a surrogate for overall survival in neoadjuvant clinical trials for gastroesophageal adenocarcinoma?

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial

Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis

Clinical complete response as a surrogate for pathological response in bladder cancer: a systematic review and meta-analysis

Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients